198210-37-6

Basic information

• Product Name: 4,7,10,13-Tetraoxa-3-silapentadecan-15-ol, 2,2-dimethyl-3,3-diphenyl-
• CAS NO: 198210-37-6
• Molecular Formula: C24H36O5Si
• Molecular Weight: 432.632
• Mol File: 198210-37-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 4,7,10,13-Tetraoxa-3-silapentadecan-15-ol, 2,2-dimethyl-3,3-diphenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4,7,10,13-Tetraoxa-3-silapentadecan-15-ol, 2,2-dimethyl-3,3-diphenyl-(198210-37-6)
• EPA Substance Registry System: 4,7,10,13-Tetraoxa-3-silapentadecan-15-ol, 2,2-dimethyl-3,3-diphenyl-(198210-37-6)

Safety Data

• Hazardous Substances Data: 198210-37-6(Hazardous Substances Data)

Upstream product

• 112-60-7 Tetraethylene glycol 
• 58479-61-1 tert-butylchlorodiphenylsilane 

Downstream Products

• 918132-09-9 C₃₂H₃₉NO₇Si 
• 859385-34-5 tetraethylene glycol tert-butyldiphenylsilyl tosyl diether 
• 86770-67-4 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethanol 
• 918132-13-5 C₂₉H₄₅NO₇Si 
• 918132-11-3 C₂₄H₃₇NO₅Si 

Relevant articles and documents

Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis

We report the synthesis and evaluation of a series of cell-permeable and N- versus O-selective sialyltransferase inhibitors. Inhibitor design entailed the functionalization of lithocholic acid at C(3) and at the cyclopentane ring side chain. Among the series, FCW34 and FCW66 were shown to inhibit MDA-MB-231 cell migration as effectively as ST3GALIII-gene knockdown did. FCW34 was shown to inhibit tumor growth, reduce angiogenesis, and delay cancer cell metastasis in animal models. Furthermore, FCW34 inhibited vessel development and suppressed angiogenic activity in transgenic zebrafish models. Our results provide clear evidence that FCW34-induced sialyltransferase inhibition reduces cancer cell metastasis by decreasing N-glycan sialylation, thus altering the regulation of talin/integrin/FAK/paxillin and integrin/NFκB signaling pathways.

COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS

Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/ infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

New deuterated oligo(ethylene glycol) building blocks and their use in the preparation of surface active lipids possessing labeled hydrophilic tethers

(Chemical Equation Presented) For the introduction of additional analysis protocols of tethered molecules, a method is presented to prepare functionalized, deuterated oligo(ethylene glycols) from ethylene glycol-d 4. Partial oligomerization of ethylene glycol-d4 and conversion to ditosylates is accompanied by coupling reactions to prepare doubly benzyl protected oligo(ethylene glycols) with two to five repeating units. The tetramer bearing 16 deuteria was elaborated at both ends to eventually prepare 2,3-di-O-phytanyl-sn-glycerol-1-tetraethylene glycol-D,L-α-lipoic acid ester (DPTL), which bears a fully deuterated tetra(ethylene glycol) spacer group. Through linking of functionalized components, an analogue of DPTL possessing an octa(ethylene glycol) spacer group was prepared, both in deuterated and unlabeled form.